Q-linea AB (publ) (QLINEA) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, everyone. Welcome and thank you for joining this presentation of Qlinia's Q3 report. You have Stuart Gander here, President and CEO, and I'm joined by my CFO, Krister Samuelsson. So we'll do this a little bit following our traditional process here. Just a quick disclaimer that we'll take as read and understood. and moving ahead to the topics for today. So I will start, as usual, with a commercial update. I will share some of the feedback that we're getting from customers in our various interactions and some of that word of mouth that's starting to spread very nicely between customers. I will talk about our priorities here for Q4 to close out the year strong before handing it over to Christa, who will walk through our financials for the quarter. And as ever, at the end, we'll reserve time for your questions. All right. And for those who just have a few minutes to join us, a few key messages that I would like to emphasize and for everyone to walk away with today. So the first one, you know, the quarter was a strong one vis-a-vis consumables demand on the instruments. A couple of things driving that. Firstly, we had a large number of instruments that were sold during COVID. Q2 and Q1 that were activated during the quarter. Those obviously started to pull through volumes. Then we continue to see some increases in, let's say, same instrument pull through as customers are getting their protocols worked through and are starting to test on the larger set of their patients. Overall, the commercial pipeline continues to grow very nicely. The US team has expanded their number of customers that they're speaking to, and particularly in the, let's say, the front end of the pipeline or where we expect the contracts to come through is starting to build up. So we've got over a...